Impact of early life AT
Angiotensin II Type 1 Receptor Blockers
/ pharmacology
Animals
Animals, Newborn
Biomarkers
/ metabolism
Cardiomyopathies
/ chemically induced
Diastole
/ drug effects
Disease Models, Animal
Fibrosis
Heart
/ drug effects
Heart Ventricles
/ drug effects
Losartan
/ pharmacology
Myocardium
/ pathology
Oxygen
/ adverse effects
Rats
Rats, Sprague-Dawley
Receptor, Angiotensin, Type 1
/ metabolism
Renin-Angiotensin System
/ drug effects
Systole
/ drug effects
Time Factors
Cardiac
Cardiomyopathy
Developmental programming
Hyperoxia
Preterm birth
Renin angiotensin system
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
05 Oct 2019
05 Oct 2019
Historique:
received:
14
04
2019
revised:
23
07
2019
accepted:
31
07
2019
pubmed:
4
8
2019
medline:
9
1
2020
entrez:
4
8
2019
Statut:
ppublish
Résumé
We previously reported that neonatal blockade of angiotensin II AT
Identifiants
pubmed: 31376367
pii: S0014-2999(19)30537-0
doi: 10.1016/j.ejphar.2019.172585
pii:
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Biomarkers
0
Receptor, Angiotensin, Type 1
0
Losartan
JMS50MPO89
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
172585Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.